11/15
06:59 am
imnm
Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
High
Report
Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
11/14
08:15 am
imnm
Immunome, Inc. (NASDAQ: IMNM) had its price target lowered by analysts at Piper Sandler from $23.00 to $21.00. They now have an "overweight" rating on the stock.
Medium
Report
Immunome, Inc. (NASDAQ: IMNM) had its price target lowered by analysts at Piper Sandler from $23.00 to $21.00. They now have an "overweight" rating on the stock.
11/13
06:12 pm
imnm
Immunome, Inc GAAP EPS of -$0.78 misses by $0.21 [Seeking Alpha]
Medium
Report
Immunome, Inc GAAP EPS of -$0.78 misses by $0.21 [Seeking Alpha]
11/13
04:05 pm
imnm
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update
11/5
08:00 am
imnm
Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
Low
Report
Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
11/1
04:05 pm
imnm
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/29
08:00 am
imnm
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
Low
Report
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
10/25
11:26 am
imnm
Immunome, Inc. (NASDAQ: IMNM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.
Medium
Report
Immunome, Inc. (NASDAQ: IMNM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.
10/18
08:00 am
imnm
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
Medium
Report
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
10/8
04:55 pm
imnm
Immunome files to sell 230K shares of common stock for holders [Seeking Alpha]
Medium
Report
Immunome files to sell 230K shares of common stock for holders [Seeking Alpha]
10/8
08:05 am
imnm
Immunome Appoints Roee Shahar as Executive Vice President, Commercial
Medium
Report
Immunome Appoints Roee Shahar as Executive Vice President, Commercial
10/8
08:00 am
imnm
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/13
07:00 am
imnm
Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
Medium
Report
Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
8/29
08:00 am
imnm
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Neutral
Report
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference